|
|
|
|
|||||
|
|
|
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the top strong buy stocks under $5 to buy now. Piper Sandler analyst Biren Amin maintained a Buy rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on August 18, setting a price target of $9.00.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its fiscal Q2 2025 results on August 12, reporting $312.8 million in cash and cash equivalents as of June 30.
Management stated that this reflects the “gross proceeds of $230.0 million from the May 2025 follow-on financing, including full exercise of the underwriters’ option to purchase additional shares”.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) expects its current cash resources to support its planned operating expenses and capital requirements into 2028.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company that develops and commercializes adeno-associated virus (AAV) based gene therapies to treat monogenic diseases of the central nervous system.
While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Aug-25 | |
| Aug-13 | |
| Aug-12 | |
| Aug-12 | |
| Aug-11 | |
| Aug-07 | |
| Aug-05 | |
| Aug-04 | |
| Aug-04 | |
| Aug-01 | |
| Aug-01 | |
| Jul-22 | |
| Jul-16 | |
| Jul-03 | |
| Jul-03 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite